Beigene Q2 revenue surged by 42%, Baiyueze's global revenue approached USD 1 billion, and the full-year guidance was raised | Financial Report Insights
Beigene's Q2 total revenue reached USD 1.3 billion, a year-on-year increase of 42%. The operating profit turned from loss to profit, and the global revenue of the core product Tislelizumab increased by 49% year-on-year. The company raised its full-year revenue guidance to USD 5-5.3 billion and maintained its expectation of positive operating profit for the full year. Beigene's U.S. stock rose over 4% in pre-market trading
Beigene's Q2 revenue reached $1.3 billion, with operating profit turning from loss to profit, and global revenue from its core product, Brukinsa, reached $950 million, a year-on-year increase of 49%. The company has raised its full-year revenue guidance to $5.0-5.3 billion and maintains its expectation of positive operating profit for the year.
On August 6, Beigene announced its unaudited financial results for Q2 and the first half of 2025:
- Q2 total revenue of $1.3 billion, a year-on-year increase of 42%; among which, global revenue from Brukinsa reached $950 million, a year-on-year increase of 49%.
- GAAP operating profit of $87.89 million, turning from a loss of $107 million in the same period last year;
- Net profit of $94.32 million, compared to a loss of $120 million in the same period last year;
- GAAP diluted earnings per ADS of $0.84, non-GAAP diluted earnings per ADS of $2.25;
- Free cash flow of $220 million;
- Gross margin increased to 87.4% (85% in the same period last year).
In the first half of 2025, Beigene's total revenue was $2.43 billion, a year-on-year increase of 45%. The GAAP operating profit for the first half was $98.99 million, compared to a loss of $369 million in the same period last year. The net profit for the first half was $95.59 million, compared to a loss of $372 million in the same period last year.
Beigene's U.S. stock pre-market rose over 4%.
Global Revenue from Brukinsa Approaches $1 Billion, Overseas Expansion Continues to Gain Momentum
Beigene Limited's main business is the research, development, production, and commercialization of innovative drugs. The company's main products include Brukinsa, Tislelizumab, Abivertinib, and others.
The core product Brukinsa is used to treat two types of relapsed/refractory lymphomas (relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)). In the second quarter, global revenue from Brukinsa reached $950 million, a year-on-year increase of 49%.
Notably, the change in regional distribution is worth attention: The U.S. market contributed $684 million, a growth of 43%; while the European market achieved explosive growth with revenue of $150 million, an increase of 85%, demonstrating the effectiveness of the company's internationalization strategy. Beigene's management claims that Brukinsa "continues to maintain a leading market share of new patients among BTK inhibitor drugs." In addition to the star product Baiyueze, the company claims it will achieve over 20 R&D milestones in the next 18 months. In terms of specific progress, Sotoclar (BCL2 inhibitor) has received priority review in China, and BGB-16673 has obtained European PRIME designation, indicating regulatory recognition of its innovative value.
Particularly noteworthy is the progress in the solid tumor pipeline. Onidatuzumab has been approved in China for second-line treatment of HER2-positive biliary tract cancer and has been commercialized, opening up new growth opportunities for the company beyond hematologic tumors.
The company has raised its full-year revenue guidance to $5-5.3 billion and maintains its expectation of positive operating profit for the year
